Last reviewed · How we verify
Ethazole — Competitive Intelligence Brief
phase 2
sulfaethidole
RAC-alpha serine/threonine-protein kinase
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Ethazole (SULFAETHIDOLE). Ethazole works by inhibiting the RAC-alpha serine/threonine-protein kinase enzyme, which plays a crucial role in cell signaling pathways.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ethazole TARGET | SULFAETHIDOLE | phase 2 | sulfaethidole | RAC-alpha serine/threonine-protein kinase | ||
| Impavido | MILTEFOSINE | Knight Theraps | marketed | Antileishmanial [EPC] | RAC-alpha serine/threonine-protein kinase | 2014-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (sulfaethidole class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ethazole CI watch — RSS
- Ethazole CI watch — Atom
- Ethazole CI watch — JSON
- Ethazole alone — RSS
- Whole sulfaethidole class — RSS
Cite this brief
Drug Landscape (2026). Ethazole — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfaethidole. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing